Skip to main content

Articles

Page 4 of 102

  1. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves
    Citation: Breast Cancer Research 2021 23:32

    The original article was published in Breast Cancer Research 2021 23:25

  2. Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor...

    Authors: Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon and François-Clément Bidard
    Citation: Breast Cancer Research 2021 23:31
  3. Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclin...

    Authors: Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres and Eddy S. Yang
    Citation: Breast Cancer Research 2021 23:30
  4. MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with c...

    Authors: Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava…
    Citation: Breast Cancer Research 2021 23:29
  5. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf
    Citation: Breast Cancer Research 2021 23:28

    The original article was published in Breast Cancer Research 2021 23:20

  6. Patients diagnosed with metastatic breast cancer have poor outcome with a median survival of approximately 2 years. While novel therapeutic options are urgently needed, the great majority of breast cancer rese...

    Authors: Jenny Stenström, Ingrid Hedenfalk and Catharina Hagerling
    Citation: Breast Cancer Research 2021 23:27
  7. Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lack...

    Authors: Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch…
    Citation: Breast Cancer Research 2021 23:26
  8. Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of D...

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves
    Citation: Breast Cancer Research 2021 23:25

    The Correction to this article has been published in Breast Cancer Research 2021 23:32

  9. Estimates of contralateral breast cancer (CBC) risk in the modern treatment era by year of diagnosis and characteristics of the first breast cancer are needed to assess the impact of recent advances in breast ...

    Authors: Cody Ramin, Diana R. Withrow, Brittny C. Davis Lynn, Gretchen L. Gierach and Amy Berrington de González
    Citation: Breast Cancer Research 2021 23:24
  10. Cyclooxygenase 2 (COX-2) promotes stemness in triple negative breast cancer (TNBC), highlighting COX-2 as a promising therapeutic target in these tumors. However, to date, clinical trials using COX-2 inhibitor...

    Authors: Jun Tian, Vivian Wang, Ni Wang, Baharak Khadang, Julien Boudreault, Khldoun Bakdounes, Suhad Ali and Jean-Jacques Lebrun
    Citation: Breast Cancer Research 2021 23:23
  11. The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and the Tyrer-Cuzick breast cancer risk prediction models are commonly used in clinical practice and have recent...

    Authors: Parichoy Pal Choudhury, Mark N. Brook, Amber N. Hurson, Andrew Lee, Charlotta V. Mulder, Penny Coulson, Minouk J. Schoemaker, Michael E. Jones, Anthony J. Swerdlow, Nilanjan Chatterjee, Antonis C. Antoniou and Montserrat Garcia-Closas
    Citation: Breast Cancer Research 2021 23:22
  12. FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their distri...

    Authors: Silvana Mouron, Luis Manso, Eduardo Caleiras, Jose L. Rodriguez-Peralto, Oscar M. Rueda, Carlos Caldas, Ramon Colomer, Miguel Quintela-Fandino and Maria J. Bueno
    Citation: Breast Cancer Research 2021 23:21
  13. Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because of an incomplete accounting for underlying molecula...

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf
    Citation: Breast Cancer Research 2021 23:20

    The Correction to this article has been published in Breast Cancer Research 2021 23:28

  14. Frailty is associated with an increased risk of chemotherapy toxicity. Cellular markers of inflammation can help identify patients with frailty characteristics. However, the role of cellular markers of inflamm...

    Authors: Nikesha Gilmore, Supriya Mohile, Lianlian Lei, Eva Culakova, Mostafa Mohamed, Allison Magnuson, Kah Poh Loh, Ronald Maggiore, Elizabeth Belcher, Alison Conlin, Lora Weiselberg, Mary Ontko and Michelle Janelsins
    Citation: Breast Cancer Research 2021 23:19
  15. To evaluate weight change patterns over time following the diagnosis of breast cancer and to examine the association of post-diagnosis weight change and survival outcomes in Black and White patients.

    Authors: Lihua Shang, Masaya Hattori, Gini Fleming, Nora Jaskowiak, Donald Hedeker, Olufunmilayo I. Olopade and Dezheng Huo
    Citation: Breast Cancer Research 2021 23:18
  16. In breast cancer, immunohistochemistry (IHC) subtypes, together with grade and stage, are well-known independent predictors of breast cancer death. Given the immense changes in breast cancer treatment and surv...

    Authors: Anna L. V. Johansson, Cassia B. Trewin, Irma Fredriksson, Kristin V. Reinertsen, Hege Russnes and Giske Ursin
    Citation: Breast Cancer Research 2021 23:17
  17. The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing brea...

    Authors: Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman and Andreas H. Hielscher
    Citation: Breast Cancer Research 2021 23:16
  18. It is well established that tumors are antigenic and can induce an immune response by the host, entailing lymphocytic infiltration of the tumor and surrounding stroma. The extent and composition of the immune ...

    Authors: Thomas E. Rohan, Rhonda Arthur, Yihong Wang, Sheila Weinmann, Mindy Ginsberg, Sherene Loi and Roberto Salgado
    Citation: Breast Cancer Research 2021 23:15
  19. There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus...

    Authors: Mariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai and Sarah Mougalian
    Citation: Breast Cancer Research 2021 23:14
  20. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Zaklina Kovacevic, Des R. Richardson, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm…
    Citation: Breast Cancer Research 2021 23:13

    The original article was published in Breast Cancer Research 2020 22:75

  21. MicroRNAs have been reported to participate in tumorigenesis, treatment resistance, and tumor metastasis. Novel microRNAs need to be identified and investigated to guide the clinical prognosis or therapy for b...

    Authors: Chong Chen, Yundi Pan, Lipeng Bai, Huilin Chen, Zhaojun Duan, Qin Si, Ruizhe Zhu, Tsung-Hsien Chuang and Yunping Luo
    Citation: Breast Cancer Research 2021 23:12
  22. Triple-negative breast cancer (BCa) (TNBC) is a deadly form of human BCa with limited treatment options and poor prognosis. In our prior analysis of over 2200 breast cancer samples, the G protein-coupled recep...

    Authors: Xuanmao Jiao, Min Wang, Zhao Zhang, Zhiping Li, Dong Ni, Anthony W. Ashton, Hsin-Yao Tang, David W. Speicher and Richard G. Pestell
    Citation: Breast Cancer Research 2021 23:11
  23. Basal-like breast cancers (BLBCs) are a leading cause of cancer death due to their capacity to metastasize and lack of effective therapies. More than half of BLBCs have a dysfunctional BRCA1. Although most BRCA1-...

    Authors: Feng Bai, Shiqin Liu, Xiong Liu, Daniel P. Hollern, Alexandria Scott, Chuying Wang, Lihan Zhang, Cheng Fan, Li Fu, Charles M. Perou, Wei-Guo Zhu and Xin-Hai Pei
    Citation: Breast Cancer Research 2021 23:10
  24. Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multice...

    Authors: Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi…
    Citation: Breast Cancer Research 2021 23:9
  25. Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xe...

    Authors: Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero…
    Citation: Breast Cancer Research 2021 23:8
  26. Invasive pleomorphic lobular carcinoma (PLC) of the breast is a subtype of invasive lobular cancer which compromises approximately 1% of all epithelial breast malignancies and is characterized by higher nuclea...

    Authors: Gregory M. Riedlinger, Sonali Joshi, Kim M. Hirshfield, Nicola Barnard and Shridar Ganesan
    Citation: Breast Cancer Research 2021 23:7
  27. Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpin...

    Authors: Amy E. McCart Reed, Lauren Kalinowski, Peter T. Simpson and Sunil R. Lakhani
    Citation: Breast Cancer Research 2021 23:6
  28. Existence of breast cancer stem cells (BCSCs) is implicated in disease relapse, metastasis, and resistance of treatment. β1,3-Galactosyltransferase 5 (B3GALT5) has been shown to be a pro-survival marker for BC...

    Authors: Yu-Mei Liao, Ya-Hui Wang, Jung-Tung Hung, Yu-Ju Lin, Yen-Lin Huang, Guo-Shiou Liao, Ya-Ling Hsu, Jen-Chien Wu and Alice L. Yu
    Citation: Breast Cancer Research 2021 23:5
  29. NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric ...

    Authors: Karen D. Howarth, Tashfina Mirza, Susanna L. Cooke, Suet-Feung Chin, Jessica C. Pole, Ernest Turro, Matthew D. Eldridge, Raquel Manzano Garcia, Oscar M. Rueda, Chris Boursnell, Jean E. Abraham, Carlos Caldas and Paul A. W. Edwards
    Citation: Breast Cancer Research 2021 23:3
  30. The H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer, but are operator-de...

    Authors: Katherine Sanchez, Isaac Kim, Brie Chun, Joanna Pucilowska, William L. Redmond, Walter J. Urba, Maritza Martel, Yaping Wu, Mary Campbell, Zhaoyu Sun, Gary Grunkemeier, Shu Ching Chang, Brady Bernard and David B. Page
    Citation: Breast Cancer Research 2021 23:2
  31. Endocrine therapy resistance is a hallmark of advanced estrogen receptor (ER)-positive breast cancer. In this study, we aimed to determine acquired genomic changes in endocrine-resistant disease.

    Authors: Nolan Priedigkeit, Kai Ding, William Horne, Jay K. Kolls, Tian Du, Peter C. Lucas, Jens-Uwe Blohmer, Carsten Denkert, Anna Machleidt, Barbara Ingold-Heppner, Steffi Oesterreich and Adrian V. Lee
    Citation: Breast Cancer Research 2021 23:1
  32. Tumour-infiltrating lymphocytes (TILs) are of important prognostic and predictive value in human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC),...

    Authors: Christine Lundgren, Pär-Ola Bendahl, Maria Ekholm, Mårten Fernö, Carina Forsare, Ute Krüger, Bo Nordenskjöld, Olle Stål and Lisa Rydén
    Citation: Breast Cancer Research 2020 22:140
  33. Lysosomal cysteine protease cathepsin V has previously been shown to exhibit elevated expression in breast cancer tissue and be associated with distant metastasis. Research has also identified that cathepsin V...

    Authors: Naphannop Sereesongsaeng, Sara H. McDowell, James F. Burrows, Christopher J. Scott and Roberta E. Burden
    Citation: Breast Cancer Research 2020 22:139
  34. Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be associated with breast cancer risk, but previous studies of the association are equivocal and limited by incomplete bl...

    Authors: Gordon P. Watt, Janice Sung, Elizabeth A. Morris, Saundra S. Buys, Angela R. Bradbury, Jennifer D. Brooks, Emily F. Conant, Susan P. Weinstein, Despina Kontos, Meghan Woods, Sarah V. Colonna, Xiaolin Liang, Matthew A. Stein, Malcolm C. Pike and Jonine L. Bernstein
    Citation: Breast Cancer Research 2020 22:138
  35. Survival rates for breast cancer (BC) have improved, but quality of life post-diagnosis/treatment can be adversely affected, with survivors reporting a constellation of psychoneurological symptoms (PNS) includ...

    Authors: Areej A. Alhareeri, Kellie J. Archer, Han Fu, Debra E. Lyon, R. K. Elswick Jr, Debra L. Kelly, Angela R. Starkweather, Lynne W. Elmore, Yahya A. Bokhari and Colleen K. Jackson-Cook
    Citation: Breast Cancer Research 2020 22:137
  36. Breast cancers acquire aggressive capabilities via epithelial to mesenchymal transition (EMT), in which various integrins/integrin-linked kinase signalling are upregulated.

    Authors: Razan Wafai, Elizabeth D. Williams, Emma de Souza, Peter T. Simpson, Amy E. McCart Reed, Jamie R. Kutasovic, Mark Waltham, Cameron E. Snell, Tony Blick, Erik W. Thompson and Honor J. Hugo
    Citation: Breast Cancer Research 2020 22:136
  37. The lack of specificity and high degree of false positive and false negative rates when using mammographic screening for detecting early-stage breast cancer is a critical issue. Blood-based molecular assays th...

    Authors: Claudia Fredolini, Khyatiben V. Pathak, Luisa Paris, Kristina M. Chapple, Kristine A. Tsantilas, Matthew Rosenow, Tony J. Tegeler, Krystine Garcia-Mansfield, Davide Tamburro, Weidong Zhou, Paul Russo, Samuele Massarut, Francesco Facchiano, Claudio Belluco, Ruggero De Maria, Enrico Garaci…
    Citation: Breast Cancer Research 2020 22:135
  38. Inflammatory breast cancer (IBC) is a rare but aggressive carcinoma characterized by severe erythema and edema of the breast, with many patients presenting in advanced metastatic disease. The “inflammatory” na...

    Authors: Sandra V. Fernandez, Alexander W. MacFarlane IV, Mowafaq Jillab, Maria F. Arisi, Jennifer Yearley, Lakshmanan Annamalai, Yulan Gong, Kathy Q. Cai, R. Katherine Alpaugh, Massimo Cristofanilli and Kerry S. Campbell
    Citation: Breast Cancer Research 2020 22:134
  39. Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of...

    Authors: Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniels, Krishan Taneja, Benjamin Y. Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony Letai, Joel D. Leverson, Vincent Blot, Roderick T. Bronson, Deborah A. Dillon and Joan S. Brugge
    Citation: Breast Cancer Research 2020 22:132
  40. We aimed to examine the safety and efficacy of bevacizumab and carboplatin in patients with breast cancer brain metastases.

    Authors: Jose Pablo Leone, Kyrre E. Emblem, Michelle Weitz, Rebecca S. Gelman, Bryan P. Schneider, Rachel A. Freedman, Jerry Younger, Marco C. Pinho, A. Gregory Sorensen, Elizabeth R. Gerstner, Gordon Harris, Ian E. Krop, Daniel Morganstern, Jessica Sohl, Jiani Hu, Elizabeth Kasparian…
    Citation: Breast Cancer Research 2020 22:131
  41. Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment...

    Authors: Kyung-Min Lee, Hyebin Lee, Dohyun Han, Woo Kyung Moon, Kwangsoo Kim, Hyeon Jeong Oh, Jinwoo Choi, Eun Hye Hwang, Seong Eun Kang, Seock-Ah Im, Kyung-Hun Lee and Han Suk Ryu
    Citation: Breast Cancer Research 2020 22:130
  42. Menopausal hormone therapy (MHT) increases breast cancer (BC) risk, but cohort studies largely consider use only at enrollment. Evidence is limited on how changes in MHT use alter the magnitude of risk, and wh...

    Authors: Shao-Ming Wang, Ruth M. Pfeiffer, Gretchen L. Gierach and Roni T. Falk
    Citation: Breast Cancer Research 2020 22:129
  43. Extracellular vesicles (EVs) are small membrane particles that contribute to cancer progression and metastases by transporting biologically significant proteins and nucleic acids. They may also serve as biomar...

    Authors: Kimberly R. Jordan, Jessica K. Hall, Troy Schedin, Michelle Borakove, Jenny J. Xian, Monika Dzieciatkowska, Traci R. Lyons, Pepper Schedin, Kirk C. Hansen and Virginia F. Borges
    Citation: Breast Cancer Research 2020 22:128
  44. Based on the androgen receptor (AR) expression, triple-negative breast cancer (TNBC) can be subdivided into AR-positive TNBC and AR-negative TNBC, also known as quadruple-negative breast cancer (QNBC). QNBC ch...

    Authors: Shristi Bhattarai, Geetanjali Saini, Keerthi Gogineni and Ritu Aneja
    Citation: Breast Cancer Research 2020 22:127
  45. Activating transcription factor-2 (ATF2), a member of the leucine zipper family of DNA binding proteins, has been implicated as a tumour suppressor in breast cancer. However, its exact role in breast cancer en...

    Authors: Athina Giannoudis, Mohammed Imad Malki, Bharath Rudraraju, Hisham Mohhamed, Suraj Menon, Triantafillos Liloglou, Simak Ali, Jason S. Carroll and Carlo Palmieri
    Citation: Breast Cancer Research 2020 22:126
  46. CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal...

    Authors: Ozlen Balcioglu, Richard E. Heinz, David W. Freeman, Brooke L. Gates, Berhane M. Hagos, Evan Booker, Elnaz Mirzaei Mehrabad, Hyrum T. Diesen, Kishan Bhakta, Supraja Ranganathan, Masami Kachi, Mathias Leblanc, Peter C. Gray and Benjamin T. Spike
    Citation: Breast Cancer Research 2020 22:125
  47. Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explo...

    Authors: Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes…
    Citation: Breast Cancer Research 2020 22:124
  48. 27-Hydroxycholesterol (27HC) stimulates estrogen receptor-positive (ER+) breast cancer (BC) progression. Inhibiting the sterol 27-hydroxylase (CYP27A1) abrogates these growth-promoting effects of 27HC in mice....

    Authors: Siker Kimbung, Maria Inasu, Tor Stålhammar, Björn Nodin, Karin Elebro, Helga Tryggvadottir, Maria Ygland Rödström, Karin Jirström, Karolin Isaksson, Helena Jernström and Signe Borgquist
    Citation: Breast Cancer Research 2020 22:123

Annual Journal Metrics